Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

BioAge Labs (BIOA) announced that it will present new preclinical data for its lead product candidate azelaprag, an orally available small ...

Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

Follow us on Facebook and join our Telegram channel for the latest updates. A chef made famous by a hit Netflix show is poised to boost South Korea’s struggling IPO market, listing his restaurant ...

Drug developers have achieved resounding success in the fall U.S. IPO market, with all the $100-million plus offerings since September upsized. Robust debuts by drug developers Bicara Therapeutics , ...

Septerna, in which Goldman owns a 5.4% stake, now aims to raise $275 million by selling nearly 15.3 million shares priced at $18 apiece. Drug developers have achieved resounding success in the fall U.

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in ...

Hyundai Motors India IPO highlights: The Hyundai Motor IPO was subscribed 2.37 times overall by the close of bidding on October 17, 2024 (Day 3). Hyundai Motor IPO India Subscription Status ...

Hyundai IPO allotment: Share allotment for Hyundai Motor India IPO is expected on October 18, with shares listing on BSE and NSE on October 22. Hyundai Motor India's initial public offering (IPO ...